Evidence map›Paper›PMID 39119719›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2024

Hospital surveillance of respiratory viruses during the COVID-19 pandemic and beyond: contribution to the WHO mosaic framework, Israel, 2020 to 2023.

Lea Gur-Arie, Michal Stein, Hanna Sefty, Ilana S Fratty, Ital Nemet, Limor Kliker, Nofar Atari, Neta S Zuckerman, Alina Rosenberg, Heftziba Ivgi and 8 more

Abstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Lea Gur-ArieIsrael Center for Disease Control, Israel Ministry of Health, Tel Hashomer, Ramat Gan, Israel.
Michal SteinPediatric Infectious Diseases Unit, Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Hanna SeftyIsrael Center for Disease Control, Israel Ministry of Health, Tel Hashomer, Ramat Gan, Israel.
Ilana S FrattyIsrael Center for Disease Control, Israel Ministry of Health, Tel Hashomer, Ramat Gan, Israel.
Ital NemetCentral Virology Laboratory, Ministry of Health, Tel Hashomer, Ramat Gan, Israel.
Limor KlikerCentral Virology Laboratory, Ministry of Health, Tel Hashomer, Ramat Gan, Israel.
Nofar AtariCentral Virology Laboratory, Ministry of Health, Tel Hashomer, Ramat Gan, Israel.
Neta S ZuckermanCentral Virology Laboratory, Ministry of Health, Tel Hashomer, Ramat Gan, Israel.
Alina RosenbergIsrael Center for Disease Control, Israel Ministry of Health, Tel Hashomer, Ramat Gan, Israel.
Heftziba IvgiImmunology and Virology Laboratory, Sha'are-Zedek Medical Center, Jerusalem, Israel.
Orit Golan-ShanyBnai-Zion Medical Center, Microbiology Laboratory, Haifa, Israel.
Nadav SorekMicrobiology Laboratory, Assuta Ashdod University Hospital, Ashdod, Israel.
Orna Schwartz-HarariMicrobiology Laboratory, Edith Wolfson Medical Center, Holon, Israel.
Michal BrombergIsrael Center for Disease Control, Israel Ministry of Health, Tel Hashomer, Ramat Gan, Israel.
Lital Keinan-BokerIsrael Center for Disease Control, Israel Ministry of Health, Tel Hashomer, Ramat Gan, Israel.
Michal MandelboimCentral Virology Laboratory, Ministry of Health, Tel Hashomer, Ramat Gan, Israel.
Aharona Glatman-FreedmanIsrael Center for Disease Control, Israel Ministry of Health, Tel Hashomer, Ramat Gan, Israel.
Israeli Respiratory Viruses Hospital Laboratory Network (IRVHLN)The members of the Israeli Respiratory Viruses Hospital Laboratory Network (IRVHLN) are acknowledged at the end of the article.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundA new respiratory virus surveillance platform, based on nationwide hospital laboratory data, was established in Israel during the COVID-19 pandemic.AimWe aimed to evaluate the performance of this platform with respect to the detection of influenza and respiratory syncytial virus (RSV) from week 36 in 2020 to week 15 in 2023, and how it fits with the World Health Organization (WHO) mosaic surveillance framework.MethodsData of respiratory samples from hospitalised patients sent for laboratory confirmation of influenza virus or RSV from 25 general hospital laboratories nationwide were collected. We analysed the weekly number and percentage of samples positive for influenza virus or RSV vis-à-vis SARS-CoV-2 activity and compared data from the new surveillance platform with existing surveillance platforms. Using data in the new surveillance platform, we analysed early stages of a 2021 out-of-season RSV outbreak and evaluated the capabilities of the new surveillance system with respect to objectives and domains of the WHO mosaic framework.ResultsThe new hospital-laboratory surveillance platform captured the activity of influenza virus and RSV, provided crucial data when outpatient sentinel surveillance was not operational and supported an out-of-season RSV outbreak investigation. The new surveillance platform fulfilled important objectives in all three domains of the mosaic framework and could serve for gathering additional information to fulfil more domain objectives.ConclusionThe new hospital laboratory surveillance platform provided essential data during the COVID-19 pandemic and beyond, fulfilled important domain objectives of the mosaic framework and could be adapted for the surveillance of other viruses.

Indexed as

COVID-19Influenza, HumanPandemicsRespiratory Syncytial Virus InfectionsSARS-CoV-2World Health OrganizationHumansIsraelLaboratories, HospitalPopulation SurveillanceRespiratory Syncytial Virus, HumanSentinel SurveillanceCOVID-19influenza virusmosaic frameworkpandemicrespiratory syncytial virusrespiratory virusesRSVSARS-CoV-2surveillance

Identifiers

PMID39119719
PMCPMC11312018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.